Free Trial
NASDAQ:THAR

Tharimmune Q1 2024 Earnings Report

Tharimmune logo
$1.68 -0.01 (-0.59%)
Closing price 07/15/2025 03:55 PM Eastern
Extended Trading
$1.75 +0.07 (+4.17%)
As of 07/15/2025 05:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tharimmune EPS Results

Actual EPS
-$2.85
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Tharimmune Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Tharimmune Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Thursday, May 9, 2024
Conference Call Time
7:00AM ET

Earnings Documents

Tharimmune Earnings Headlines

Tharimmune CFO Don Kim Resigns
Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
See More Tharimmune Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tharimmune? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tharimmune and other key companies, straight to your email.

About Tharimmune

Tharimmune (NASDAQ:THAR) is a clinical-stage biotechnology company dedicated to developing novel immuno-activating therapies for life-threatening infectious, inflammatory and hemorrhagic conditions. The company employs a proprietary platform of synthetic innate immune receptor agonists, designed to harness and amplify the body’s natural defenses against bacterial infections, sepsis and related organ injuries. Tharimmune’s lead program targets acute conditions where rapid activation of innate immunity can reduce pathogen burden, curb systemic inflammation and improve clinical outcomes.

Founded in 2016 and headquartered in Seattle, Washington, Tharimmune emerged from academic collaborations with leading immunologists and infectious disease researchers. The company’s pipeline includes multiple preclinical candidates optimized for potency, safety and manufacturability. Their flagship TLR4 agonist is being advanced toward IND-enabling studies for sepsis and acute kidney injury, while additional programs focused on TLR7/8 and STING pathways seek to address multidrug-resistant pneumonia and hemorrhagic shock. Tharimmune’s synthetic molecules are designed for scalable chemical synthesis and have demonstrated robust activity in animal models.

Tharimmune maintains strategic partnerships with academic centers and contract research organizations across North America and Europe to accelerate development and manufacturing. The company’s research approach integrates immunology expertise with process chemistry, enabling rapid iteration on lead scaffolds and streamlined transition to GMP production. In parallel, Tharimmune collaborates with regulatory consultants to design adaptive clinical trial protocols and engage early with the U.S. Food and Drug Administration and the European Medicines Agency.

The leadership team at Tharimmune combines seasoned biopharma executives, infectious disease specialists and process development experts. The board and executive management draw on decades of experience from global pharmaceutical companies, academic research institutions and government agencies. Together, they guide Tharimmune’s mission to deliver first-in-class immunotherapies that address urgent unmet needs in critical care and infectious disease management.

View Tharimmune Profile

More Earnings Resources from MarketBeat